Clinical trials
35 active studies led by Ipsen, of 292 in all
Source: ClinicalTrials.gov, Studies with Ipsen (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 4Markets in public records
- 0Regions & countries
- 35Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Ipsen or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Ipsen
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
US drug approvals
6 approvals with a product on the US market
- Iqirvo NDA218860 · approved 10 Jun 2024
- Sohonos NDA215559 · approved 16 Aug 2023
- Bylvay NDA215498 · approved 20 Jul 2021
- Onivyde NDA207793 · approved 22 Oct 2015
- Somatuline Depot NDA022074 · approved 30 Aug 2007
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Trials over time
Studies Ipsen leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Ipsen or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Ipsen: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Ipsen is in.
From our blog
Stories on the topics Ipsen works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Alzheimer's Diagnosis: Blood Tests and Earlier Answers
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
Cannabis-Based Medicines: Science and Regulation
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Read